Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,775,900
  • Shares Outstanding, K 73,750
  • Annual Sales, $ 76,300 K
  • Annual Income, $ -122,700 K
  • EBIT $ -71 M
  • EBITDA $ -59 M
  • 60-Month Beta 1.23
  • Price/Sales 17.26
  • Price/Cash Flow N/A
  • Price/Book 6.91

Options Overview Details

View History
  • Implied Volatility 84.92% (-20.26%)
  • Historical Volatility 36.09%
  • IV Percentile 30%
  • IV Rank 21.61%
  • IV High 220.79% on 11/14/25
  • IV Low 47.46% on 08/22/25
  • Expected Move (DTE 11) 3.40 (14.02%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 33
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 6,266
  • Open Int (30-Day) 6,401
  • Expected Range 20.85 to 27.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.06
  • Number of Estimates 6
  • High Estimate 1.08
  • Low Estimate -0.52
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.93 +10.58%
on 02/23/26
25.75 -5.84%
on 03/06/26
+1.74 (+7.73%)
since 02/09/26
3-Month
21.93 +10.58%
on 02/23/26
27.94 -13.21%
on 12/22/25
-1.56 (-6.03%)
since 12/09/25
52-Week
9.03 +168.55%
on 04/10/25
28.49 -14.88%
on 11/26/25
+12.25 (+102.08%)
since 03/07/25

Most Recent Stories

More News
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 45.84 (+0.95%)
ZYME : 24.25 (+0.71%)
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 45.84 (+0.95%)
ZYME : 24.25 (+0.71%)
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026...

ZYME : 24.25 (+0.71%)
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

ZYME : 24.25 (+0.71%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

ZYME : 24.25 (+0.71%)
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive...

ZYME : 24.25 (+0.71%)
Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii) in first-line HER2-positive (HER2+)  gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI Up to $440.0 million in...

ZYME : 24.25 (+0.71%)
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the...

ZYME : 24.25 (+0.71%)
Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present...

ZYME : 24.25 (+0.71%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...

ZYME : 24.25 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 25.85
2nd Resistance Point 25.38
1st Resistance Point 24.82
Last Price 24.25
1st Support Level 23.78
2nd Support Level 23.31
3rd Support Level 22.75

See More

52-Week High 28.49
Last Price 24.25
Fibonacci 61.8% 21.06
Fibonacci 50% 18.76
Fibonacci 38.2% 16.46
52-Week Low 9.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar